Philadelphia-based cancer diagnostics start-up Proscia has raised $8.3m in a series A funding round led by Flybridge Capital Partners. The money will be used to grow the company's cloud-based digital pathology software, which used machine-imaging AI to help pathologists analyse tumours, as well as increasing marketing for its current platform. In addition to the funding, Proscia's CEO and co-founder Dr. David DeBolt said that he expects his company to have an initial public offering (IPO) within three years.
Philadelphia-based cancer diagnostics start-up Proscia has raised $8.3m in a series A funding round led by Flybridge Capital Partners. The money will be used to grow the company's cloud-based digital pathology software, which used machine-imaging AI to help pathologists analyse tumours, as well as increasing marketing for its current platform. The latest news comes after $1m in seed funding was raised by Proscia in 2016.